Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBT Margin: 2022-2025

Historic EBT Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -349.08%.

  • bioAffinity Technologies' EBT Margin fell 26406.00% to -349.08% in Q3 2025 from the same period last year, while for Sep 2025 it was -216.89%, marking a year-over-year decrease of 12688.00%. This contributed to the annual value of -96.43% for FY2024, which is 21614.00% up from last year.
  • According to the latest figures from Q3 2025, bioAffinity Technologies' EBT Margin is -349.08%, which was down 9.91% from -317.59% recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' EBT Margin peaked at 7.67% during Q2 2022, and registered a low of -427,752.87% during Q3 2022.
  • For the 3-year period, bioAffinity Technologies' EBT Margin averaged around -16,000.79%, with its median value being -143.06% (2025).
  • Data for bioAffinity Technologies' EBT Margin shows a peak YoY increase of 42,698,613bps (in 2023) and a maximum YoY decrease of 880,079bps (in 2023) over the last 5 years.
  • Over the past 4 years, bioAffinity Technologies' EBT Margin (Quarterly) stood at -71,380.39% in 2022, then soared by 7,127,328bps to -107.12% in 2023, then tumbled by 2,728bps to -134.40% in 2024, then plummeted by 26,406bps to -349.08% in 2025.
  • Its last three reported values are -349.08% in Q3 2025, -317.59% for Q2 2025, and -143.06% during Q1 2025.